Avidity Biosciences
RNA
#1835
Rank
NZ$18.68 B
Marketcap
NZ$123.99
Share price
0.13%
Change (1 day)
97.76%
Change (1 year)

Revenue for Avidity Biosciences (RNA)

Revenue in 2025 (TTM): NZ$35.88 Million

According to Avidity Biosciences's latest financial reports the company's current revenue (TTM ) is NZ$36.12 Million. In 2024 the company made a revenue of NZ$19.32 Million an increase over the revenue in the year 2023 that were of NZ$15.11 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Avidity Biosciences from 2019 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) NZ$35.88 M85.71%
2024 NZ$19.32 M27.82%
2023 NZ$15.11 M4.05%
2022 NZ$14.52 M6.41%
2021 NZ$13.65 M45.15%
2020 NZ$9.4 M173.17%
2019 NZ$3.44 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
PTC Therapeutics
PTCT
NZ$3.07 B 8,425.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Acorda Therapeutics
ACOR
NZ$0.20 B 454.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ$4.17 B 11,466.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Catalyst Pharmaceuticals
CPRX
NZ$1.00 B 2,670.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Fate Therapeutics
FATE
NZ$12.35 M-65.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Acceleron Pharma
XLRN
NZ$0.19 B 440.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$108.68 B 300,772.15%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$73.31 B 202,855.61%๐Ÿ‡ฌ๐Ÿ‡ง UK